Breaking News Instant updates and real-time market news.

NVS

Novartis

$82.55

-0.66 (-0.79%)

, KITE

Kite Pharma

$103.36

-1.29 (-1.23%)

18:12
07/13/17
07/13
18:12
07/13/17
18:12

Three drugmakers may capitalize on Novartis' cancer therapy, Barron's reports

Novartis' (NVS) novel cancer therapy, CTL019, is one step closer to hitting the market after a FDA panel unanimously voted to recommend regulatory approval, Barron's reports. Three small drugmakers, Kite Pharma (KITE), Juno Therapeutics (JUNO) and Bluebird Bio (BLUE), are looking to ride Novartis' coattails with their own drugs and may be able to capitalize on its success, Barron's added. Reference Link

NVS

Novartis

$82.55

-0.66 (-0.79%)

KITE

Kite Pharma

$103.36

-1.29 (-1.23%)

JUNO

Juno Therapeutics

$28.06

0.03 (0.11%)

BLUE

bluebird bio

$96.00

0.3 (0.31%)

  • 16

    Jul

  • 18

    Jul

  • 29

    Nov

NVS Novartis
$82.55

-0.66 (-0.79%)

07/12/17
RHCO
07/12/17
NO CHANGE
Target $108
RHCO
Buy
bluebird bio recent weakness unwarranted, says SunTrust
SunTrust analyst Edward Nash views the weakness in bluebird bio (BLUE) shares since the FDA briefing document on Novartis' (NVSR) CAR T product candidate as unwarranted. The tone of the briefing document is neutral and emphasizes short-term toxicities observed in Novartis' studies and long-term safety concerns so that the Advisory Committee will be able to conduct a thorough discussion to determine the risk/benefit ratio, Nash tells investors in a research note. Further, he believes the data from Novartis and bluebird are not an apples-to-apples comparison and reminds investors of the "differentiated safety profile" that bluebird's bb2121 has demonstrated to date. He recommends buying bluebird on the recent selloff and reiterates a Buy rating on the name with a $108 price target.
07/05/17
FBCO
07/05/17
DOWNGRADE
FBCO
Underperform
Novartis downgraded to Underperform from Neutral at Credit Suisse
Credit Suisse analyst Matthew Weston downgraded Novartis to Underperform with a price target of 77 francs.
07/13/17
SBSH
07/13/17
NO CHANGE
SBSH
Novartis vote bodes well for Kite and Juno, says at Citi
Citi analyst Robyn Karnauskas believes the FDA's unanimous vote in favor of Novartis' (NVS) CAR-T bodes well for Kite Pharma (KITE) and Juno Therapeutics (JUNO). Yesterday's panel meeting provides a preview of what Kite can expect ahead of its November 29 FDA action date, Karnauskas tells investors in a research note. She believes the expert commentary from the panel has "overarching implications" for Kite and Juno, both of which are developing CAR-T therapies for multiple indications.
07/10/17
JEFF
07/10/17
NO CHANGE
Target $121
JEFF
Buy
Jefferies ups Kite target to $121 on 'relatively benign' FDA docs
Jefferies analyst Biren Amin raised his price target for Kite Pharma (KITE) shares to $121 from $101 after the FDA posted briefing documents ahead of the July 12 committee meeting disusing Novartis' (NVS) CAR-T therapy CTL019. The documents for the first CAR-T therapy seem "relatively benign," Amin tells investors in a research note. The FDA's view of CAR-T therapies looks in-line with expectations, but the agency may require long-term follow-up of patients to assess for risk of secondary malignancies, Amin writes. He keeps a Buy rating on Kite Pharma. The stock in late morning trading is down 3% to $102.55.
KITE Kite Pharma
$103.36

-1.29 (-1.23%)

07/13/17
07/13/17
DOWNGRADE

Hold
Kite Pharma downgraded to Hold at Maxim
As previously reported, Maxim analyst Jason McCarthy downgraded Kite Pharma to Hold from Buy as he believes approval and success in relapsed/refractory blood cancers is already being factored in at the stock's current valuation. While "there is much more to come" from T-cell based oncology therapies, the focus for Kite is set to shift to "not if, but when and how much," McCarthy tells investors.
07/13/17
MAXM
07/13/17
DOWNGRADE
MAXM
Hold
Kite Pharma downgraded to Hold from Buy at Maxim
JUNO Juno Therapeutics
$28.06

0.03 (0.11%)

06/08/17
06/08/17
UPGRADE
Target $100

Buy
Kite Pharma upgraded to Buy on Axi-Cel manufacturing edge at BTIG
As previously reported, BTIG analyst Dane Leone upgraded Kite Pharma (KITE) to Buy from Neutral and set a $100 price target on the shares. Data from Novartis (NVS) and Juno (JUNO) have failed to deliver any recognizable differentiation, though Leone gives Kite "a clear win" for the manufacturing of Axi-Cel versus peers, he tells investors. The analyst sees Kite having the cleanest pathway to approval for diffuse large B-cell lymphoma and, given Kite's manufacturing edge, he estimates that Axi-Cel can take about 60% of share within the U.S. DLBCL market.
06/08/17
06/08/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Juno Therapeutics (JUNO) downgraded to Sell from Neutral at BTIG with analyst Dane Leone saying that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. 2. National Grid (NGG) downgraded to Sell from Hold at Deutsche Bank with analyst James Brand saying the company's sustainable equity cash flow yield could drop below 6% after its next regulatory review. 3. BHP Billiton (BHP) downgraded to Hold from Buy at Jefferies with analyst Christopher LaFemina saying he believes the balance sheet recap trade in mining as well as the Chinese stimulus-driven recovery in demand is over. 4. Lear (LEA) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Adam Jonas saying he expects Lear's earnings to peak this year and to fall by 20% by 2021 and expects Electrical business margins to disappoint investors due to higher development costs, increased competition, and potential lost market share. 5. Hawaiian Holdings (HA) downgraded to Hold from Buy at Deutsche Bank with analyst Michael Linenberg saying the valuation is near full following the recent rally. The analyst raised his price target for the shares to $64 from $63. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
BTIG
06/08/17
DOWNGRADE
BTIG
Sell
Juno downgraded on lateness to market, lack of differentiation at BTIG
As noted earlier, BTIG downgraded Juno to Sell from Neutral. Analyst Dane Leone says that the company's treatment for CD19 and hematologic malignancies is on track to hit the market later than competing products, while there is no "demonstrated proof" that Juno will have any advantages in the areas of efficacy or toxicity. The analyst expects the revenue generated by Juno's JCAR017 treatment to come in about $1B below consensus expectations through 2026. Target $12.
BLUE bluebird bio
$96.00

0.3 (0.31%)

07/12/17
RHCO
07/12/17
NO CHANGE
RHCO
bluebird bio weakness unjustified, says SunTrust
SunTrust analyst says that the recent weakness in bluebird bio's stock may have been partially caused by an FDA document on Novartis' CAR T product for r/r B-cell ALL. The analyst says that the "tone" of the document was "neutral," while bluebird's bb2121 has a "differentiated...strong safety profile." Nash notes that the document discusses Novartis' manufacturing process control and says that bluebird bio's experience should give it "strong expertise in manufacturing." He calls bluebird's recent weakness unjustified and keeps a $108 price target and a Buy rating on bluebird.
06/30/17
BTIG
06/30/17
DOWNGRADE
BTIG
Neutral
bluebird bio downgraded to Neutral from Buy at BTIG
BTIG analyst Dane Leone downgraded bluebird bio to Neutral from Buy, saying that he believes the stock's strong year-to-date rally has captured the positive updates from the ASCO and EHA clinical meetings and the potential of the updates from key programs expected at ASH in December.
06/27/17
RHCO
06/27/17
NO CHANGE
RHCO
bluebird bio data positive, says SunTrust
SunTrust analyst Edwrad Nash says that data on bluebird's Lenti-D drug in Cerebral Adrenoleukodystrophy was positive. He thinks that it "provides strong support" for the approval of the drug, and he keeps a Buy rating on the stock.

TODAY'S FREE FLY STORIES

FULT

Fulton Financial

$18.95

-0.3 (-1.56%)

16:32
10/17/17
10/17
16:32
10/17/17
16:32
Earnings
Fulton Financial reports Q3 EPS 28c, consensus 27c »

Net interest income for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 01

    Nov

  • 02

    Nov

MCO

Moody's

$144.13

-0.62 (-0.43%)

16:32
10/17/17
10/17
16:32
10/17/17
16:32
Hot Stocks
Moody's invests in CompStak »

Moody's has made a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 16

    Nov

SYY

Sysco

$54.83

0.08 (0.15%)

16:32
10/17/17
10/17
16:32
10/17/17
16:32
Hot Stocks
Sysco acquires HFM FoodService »

Sysco Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LECO

Lincoln Electric

$94.44

-0.43 (-0.45%)

16:31
10/17/17
10/17
16:31
10/17/17
16:31
Hot Stocks
Lincoln Electric raises quarterly dividend to 39c from 35c »

The declared quarterly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

16:30
10/17/17
10/17
16:30
10/17/17
16:30
Options
Preliminary option volume of 15.7M today »

Preliminary option volume…

CNXN

Connection

$29.23

0.09 (0.31%)

16:29
10/17/17
10/17
16:29
10/17/17
16:29
Earnings
Connection sees adjusted Q3 EPS 48c-50c, consensus 56c »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVI

Navient

$12.20

0.47 (4.01%)

16:27
10/17/17
10/17
16:27
10/17/17
16:27
Earnings
Navient reports Q3 core EPS 55c, consensus 50c »

Reports Q3 private…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

RIG

Transocean

$10.79

-0.26 (-2.35%)

, BHP

BHP Billiton

$42.42

-0.23 (-0.54%)

16:25
10/17/17
10/17
16:25
10/17/17
16:25
Hot Stocks
Transocean awarded $106M contract with BHP subsidiary »

Transocean (RIG)…

RIG

Transocean

$10.79

-0.26 (-2.35%)

BHP

BHP Billiton

$42.42

-0.23 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

UCFC

United Community Financial

$9.77

-0.18 (-1.81%)

16:21
10/17/17
10/17
16:21
10/17/17
16:21
Earnings
United Community Financial reports Q3 EPS 15c, consensus 15c »

Reports Q3 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 15

    Nov

HCLP

Hi-Crush Partners

$8.95

0.25 (2.87%)

16:21
10/17/17
10/17
16:21
10/17/17
16:21
Hot Stocks
Hi-Crush Partners resumes dividend with 15c payout, announces $100M buyback »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

BBG

Bill Barrett

$4.36

0.15 (3.56%)

16:21
10/17/17
10/17
16:21
10/17/17
16:21
Hot Stocks
Bill Barrett sees cash commodity derivative gain of $7.3M in Q3 »

Bill Barrett Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

CLR

Continental Resources

$37.31

-0.11 (-0.29%)

16:20
10/17/17
10/17
16:20
10/17/17
16:20
Hot Stocks
Continental Resources sells 1M barrels of Bakken oil for export to China »

Continental Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

VIX

Volatility Index S&P 500 Options

16:20
10/17/17
10/17
16:20
10/17/17
16:20
Options
Closing CBOE SPX and VIX Index summary for October 17th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$51.10

-0.61 (-1.18%)

16:19
10/17/17
10/17
16:19
10/17/17
16:19
Hot Stocks
Mercury Systems awarded $4.7M in orders for airborne radio frequency subsystems »

Mercury Systems received…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 07

    Nov

$NSD

NASDAQ Market Internals

16:17
10/17/17
10/17
16:17
10/17/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

16:16
10/17/17
10/17
16:16
10/17/17
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$199.48

-3.2 (-1.58%)

, UNH

UnitedHealth

$203.92

10.72 (5.55%)

16:15
10/17/17
10/17
16:15
10/17/17
16:15
General news
On The Fly: Top stock stories for Tuesday »

Stocks opened little…

NFLX

Netflix

$199.48

-3.2 (-1.58%)

UNH

UnitedHealth

$203.92

10.72 (5.55%)

JNJ

Johnson & Johnson

$140.75

4.63 (3.40%)

GS

Goldman Sachs

$236.08

-6.335 (-2.61%)

MS

Morgan Stanley

$49.13

0.19 (0.39%)

AET

Aetna

$155.91

4.47 (2.95%)

ANTM

Anthem

$187.29

3.53 (1.92%)

CNC

Centene

$93.78

2.86 (3.15%)

CI

Cigna

$187.20

2.21 (1.19%)

HUM

Humana

$240.54

3.37 (1.42%)

MOH

Molina Healthcare

$61.54

1.675 (2.80%)

WCG

WellCare

$174.06

6.14 (3.66%)

CYH

Community Health

$6.44

0.54 (9.15%)

HCA

HCA Healthcare

$76.81

1.62 (2.15%)

LPNT

LifePoint

$56.20

0.4 (0.72%)

THC

Tenet

$13.59

0.68 (5.27%)

UHS

Universal Health

$108.44

2.84 (2.69%)

HOG

Harley-Davidson

$47.51

0.94 (2.02%)

IONS

Ionis Pharmaceuticals

$63.85

2.7 (4.42%)

FCX

Freeport McMoRan

$14.93

-0.34 (-2.23%)

IPXL

Impax

$19.30

-0.65 (-3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 18

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 26

    Oct

  • 27

    Oct

  • 31

    Oct

  • 02

    Nov

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 09

    Nov

IBM

IBM

$146.41

-0.39 (-0.27%)

16:14
10/17/17
10/17
16:14
10/17/17
16:14
Hot Stocks
IBM reports Q3 Cognitive solutions revenue $4.4B, up 3% ex-currency »

Reports Q3 Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

16:14
10/17/17
10/17
16:14
10/17/17
16:14
General news
Treasury International Capital Foreign Demand for Long-Term U.S. Securities data reported »

August Treasury…

LLESY

Lendlease Group

$14.60

0.026 (0.18%)

16:14
10/17/17
10/17
16:14
10/17/17
16:14
Downgrade
Lendlease Group rating change  »

Lendlease Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$146.40

-0.4 (-0.27%)

16:13
10/17/17
10/17
16:13
10/17/17
16:13
Earnings
IBM backs FY17 adjusted EPS view of at least $13.80, consensus $13.75 »

Operating diluted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

IBM

IBM

$146.43

-0.37 (-0.25%)

16:13
10/17/17
10/17
16:13
10/17/17
16:13
Hot Stocks
IBM reports Q3 cloud revenues up 20% to $4.1B »

Third-quarter cloud…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

IBM

IBM

$146.45

-0.35 (-0.24%)

16:12
10/17/17
10/17
16:12
10/17/17
16:12
Earnings
IBM reports Q3 adjusted EPS $3.30, consensus $3.28 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 22

    Oct

  • 15

    Nov

COTY

Coty

$16.01

-0.82 (-4.87%)

16:12
10/17/17
10/17
16:12
10/17/17
16:12
Initiation
Coty initiated  »

Coty initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRS

Northern Trust

$91.10

-0.82 (-0.89%)

16:11
10/17/17
10/17
16:11
10/17/17
16:11
Hot Stocks
Northern Trust CEO Frederick Waddell to step down »

Northern Trust announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.